1 Result(s)

Article

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-H...

Mathew Vithayathil, Antonio D’Alessio… in Hepatology International (2023)